| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-10-3425 |
| P698 | PubMed publication ID | 21415214 |
| P50 | author | Julian R Molina | Q107075791 |
| P2093 | author name string | Glen J Weiss | |
| Ramesh K Ramanathan | |||
| Howard A Burris | |||
| Jeffrey R Infante | |||
| Johanna C Bendell | |||
| Mario E Lacouture | |||
| Suzanne F Jones | |||
| Raoul Tibes | |||
| Mitesh J Borad | |||
| E Gabriela Chiorean | |||
| Stew Kroll | |||
| Hank Lee | |||
| Karen Lewandowski | |||
| Virginia K Langmuir | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 2997-3004 | |
| P577 | publication date | 2011-03-17 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies | |
| P478 | volume | 17 |
| Q57045114 | A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma |
| Q57470710 | A novel PBPK modeling approach to assess cytochrome P450 mediated drug-drug interaction potential of the cytotoxic prodrug evofosfamide |
| Q36106434 | A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients |
| Q34482552 | AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia |
| Q46922239 | Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy |
| Q60924205 | An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect |
| Q38120850 | Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia |
| Q48013511 | Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia. |
| Q46905097 | Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000. |
| Q92635669 | Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer |
| Q37283967 | Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models. |
| Q27009437 | Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response |
| Q41007674 | Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. |
| Q36214623 | Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer |
| Q35637224 | Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition |
| Q56889832 | Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma |
| Q92733553 | Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity |
| Q50055297 | Hypoxia Activated Evofosfamide for Treatment of Recurrent Bevacizumab-Refractory Glioblastoma: A phase I surgical study |
| Q41467964 | Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models. |
| Q38533276 | Hypoxia in astrocytic tumors and implications for therapy |
| Q38685135 | Hypoxia inducible factors in hepatocellular carcinoma |
| Q37418248 | Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors |
| Q41671585 | Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma |
| Q38754932 | Hypoxia-Sensitive Materials for Biomedical Applications |
| Q36072569 | Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. |
| Q33657282 | Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition |
| Q49450264 | Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma |
| Q61813196 | Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials |
| Q54354000 | Hypoxia-regulated gene network in drug resistance and cancer progression. |
| Q39002822 | Hypoxia: A Double-Edged Sword in Cancer Therapy |
| Q36109993 | Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model |
| Q92129920 | Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models |
| Q38184981 | Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment. |
| Q28553729 | Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors |
| Q50103495 | Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue |
| Q39110234 | Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy |
| Q38136098 | New and emerging therapies for advanced or metastatic soft tissue sarcoma |
| Q36444369 | New drugs and combinations for the treatment of soft-tissue sarcoma: a review |
| Q33404024 | PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours |
| Q64073411 | Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy |
| Q42417074 | Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia |
| Q33417472 | Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma |
| Q46013875 | Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. |
| Q47121012 | Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept. |
| Q34257226 | Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302. |
| Q46018609 | Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies. |
| Q36938779 | Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer |
| Q34413815 | Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302. |
| Q52743608 | Synthesis and Evaluation of Radiolabeled Phosphoramide Mustard with Selectivity for Hypoxic Cancer Cells. |
| Q37700855 | TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. |
| Q47769995 | Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome |
| Q91565659 | Targeting Tumor Microenvironment by Small-Molecule Inhibitors |
| Q29615491 | Targeting hypoxia in cancer therapy |
| Q34086671 | Targeting hypoxic tumour cells to overcome metastasis. |
| Q26774750 | Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs |
| Q37229190 | Targeting the metabolic microenvironment of tumors |
| Q37274132 | Targeting the tumor microenvironment: from understanding pathways to effective clinical trials |
| Q33274710 | The evolution of systemic therapy in sarcoma. |
| Q38315670 | The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma |
| Q48114384 | Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy. |
| Q38161392 | Therapeutic targeting of hyaluronan in the tumor stroma |
| Q47772621 | Tumour acidosis: from the passenger to the driver's seat. |
Search more.